| [1] |
Sheka AC, Adeyi O, Thompson J, et al.Nonalcoholic Steatohepatitis: A Review. Jama, 2020,323:1175-1183.
|
| [2] |
Younossi ZM, Koenig AB, Abdelatif D, et al.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology,2016,64:73-84.
|
| [3] |
Cai J, Zhang XJ, Li H.The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis. Hepatology,2019,70:1026-1037.
|
| [4] |
Tsuchida T, Friedman SL.Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol,2017,14:397-411.
|
| [5] |
Dransfield I, Zagórska A, Lew ED, et al.Mer receptor tyrosine kinase mediates both tethering and phagocytosis of apoptotic cells. Cell Death Dis,2015,6:e1646.
|
| [6] |
Petta S, Valenti L, Marra F, et al.MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. J Hepatol,2016,64:682-690.
|
| [7] |
Kazankov K, J?rgensen SMD, Thomsen KL, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol, 2019,16:145-159.
|
| [8] |
Cai B, Dongiovanni P, Corey KE, et al. Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis. Cell Metab,2020,31:406-421.e407.
|
| [9] |
Sather S, Kenyon KD, Lefkowitz JB, et al.A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood, 2007,109:1026-1033.
|
| [10] |
Thorp E, Vaisar T, Subramanian M, Mautner L, et al.Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cδ, and p38 mitogen-activated protein kinase (MAPK). J Biol Chem, 2011,286:33335-33344.
|
| [11] |
Alsayed Y, Uddin S, Mahmud N, et al.Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem,2001,276:4012-4019.
|
| [12] |
Roohullah A, Cooper A, Lomax AJ, et al.A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers. Invest New Drugs, 2018,36:886-894.
|
| [13] |
He H, Mennone A, Boyer JL, et al.Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology, 2011,53:548-557.
|
| [14] |
Bartneck M, Warzecha KT, Tacke F.Therapeutic targeting of liver inflammation and fibrosis by nanomedicine. Hepatobiliary Surg Nutr, 2014,3:364-376.
|
